Kurzfassung

A single-arm, multicenter, nilotinib treatment free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line Nilotinib treatment.